Liver fibrosis: pathological features, clinical treatment and application of therapeutic nanoagents

Chen, Lin; Guo, Wenyan; Mao, Chun; Shen, Jian; Wan, Mimi

doi:10.1039/d3tb02790b

J. Mater. Chem. B

2024

DOI: 10.1039/d3tb02790b

|View full text |Cite

Liver fibrosis: pathological features, clinical treatment and application of therapeutic nanoagents

Lin Chen,

Wenyan Guo,

Chun Mao

et al.

Abstract: Liver fibrosis is a reversible damage-repair response, whose pathological features mainly include damage of hepatocytes, sinusoid capillarization, hepatic stellate cells (HSCs) activation, excessive accumulation of extracellular matrix (ECM) and inflammatory...

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 214 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Interaction of Au(iii) with amino acids: a vade mecum for medicinal chemistry and nanotechnology

Mattioli,

Cipriani,

Zerbetto

et al. 2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Interaction of Au(iii) with amino acids: a vade mecum for medicinal chemistry and nanotechnology

Mattioli,

Cipriani,

Zerbetto

et al. 2024

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

The role of ferroptosis-related non-coding RNA in liver fibrosis

Zhang,

Wu,

Jiang

et al. 2024

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Liver fibrosis represents a reversible pathophysiological process, caused by chronic inflammation stemming from hepatocyte damage. It delineates the initial stage in the progression of chronic liver disease. This pathological progression is characterized by the excessive accumulation of the extracellular matrix (ECM), which leads to significant structural disruption and ultimately impairs liver function. To date, no specific antifibrotic drugs have been developed, and advanced liver fibrosis remains largely incurable. Liver transplantation remains the sole efficacious intervention for advanced liver fibrosis; nevertheless, it is constrained by exorbitant costs and the risk of postoperative immune rejection, underscoring the imperative for novel therapeutic strategies. Ferroptosis, an emergent form of regulated cell death, has been identified as a pivotal regulatory mechanism in the development of liver fibrosis and is intricately linked with the progression of liver diseases. Recent investigations have elucidated that a diverse array of non-coding RNAs (ncRNAs), including microRNAs, long non-coding RNAs, and circular RNAs, are involved in the ferroptosis pathway, thereby modulating the progression of various diseases, including liver fibrosis. In recent years, the roles of ferroptosis and ferroptosis-related ncRNAs in liver fibrosis have attracted escalating scholarly attention. This paper elucidates the pathophysiology of liver fibrosis, explores the mechanisms underlying ferroptosis, and delineates the involvement of ncRNA-mediated ferroptosis pathways in the pathology of liver fibrosis. It aims to propose novel strategies for the prevention and therapeutic intervention of liver fibrosis.

show abstract

Mesenchymal Stromal Cell-Derived Extracellular Vesicles for Reversing Hepatic Fibrosis in 3D Liver Spheroids

Chiabotto,

Semnani,

Ceccotti

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Hepatic fibrosis, arising from prolonged liver injury, entails the activation of hepatic stellate cells (HSCs) into myofibroblast-like cells expressing alpha-smooth muscle actin (α-SMA), thereby driving extracellular matrix deposition and fibrosis progression. Strategies targeting activated HSC reversal and hepatocyte regeneration show promise for fibrosis management. Previous studies suggest that extracellular vesicles (EVs) from mesenchymal stromal cells (MSCs) can suppress HSC activation, but ensuring EV purity is essential for clinical use. This study investigated the effects of MSC-derived EVs cultured in chemically defined conditions on liver spheroids and activated HSCs. Umbilical cord- and bone marrow-derived MSCs were expanded in chemically defined media, and EVs were isolated using filtration and differential ultracentrifugation. The impact of MSC-EVs was evaluated on liver spheroids generated in Sphericalplate 5D™ and on human HSCs, both activated by transforming growth factor beta 1 (TGF-β1). MSC-EVs effectively reduced the expression of profibrotic markers in liver spheroids and activated HSCs induced by TGF-β1 stimulation. These results highlight the potential of MSC-EVs collected under chemically defined conditions to mitigate the activated phenotype of HSCs and liver spheroids, suggesting MSC-EVs as a promising treatment for hepatic fibrosis.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Liver fibrosis: pathological features, clinical treatment and application of therapeutic nanoagents

Abstract: Liver fibrosis is a reversible damage-repair response, whose pathological features mainly include damage of hepatocytes, sinusoid capillarization, hepatic stellate cells (HSCs) activation, excessive accumulation of extracellular matrix (ECM) and inflammatory...

Cited by 3 publications

References 214 publications

Interaction of Au(iii) with amino acids: a vade mecum for medicinal chemistry and nanotechnology

Interaction of Au(iii) with amino acids: a vade mecum for medicinal chemistry and nanotechnology

The role of ferroptosis-related non-coding RNA in liver fibrosis

Mesenchymal Stromal Cell-Derived Extracellular Vesicles for Reversing Hepatic Fibrosis in 3D Liver Spheroids

Contact Info

Product

Resources

About